New research published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association last month demonstrated that patients show declines in cognition, grip strength, and overall health up to several years before being diagnosed with a neurodegenerative disorder.
Based on previous work demonstrating the positive effects of exercise on symptoms of Parkinson’s disease, researchers looked at how irisin, a hormone released during exercise, affected the accumulation of misfolded alpha-synuclein in a mouse model of Parkinson’s.
Seelos Therapeutics announced it has received a grant from the Michael J. Fox Foundation for Parkinson’s Research to continue to research its gene-editing therapy, SLS-004, as a potential treatment for Parkinson’s disease.
New research presented at the European Academy of Neurology (EAN) 2022 Congress has revealed a potential link between specific gene mutations and the rate at which Parkinson’s disease progresses.
Biogen and Alectos Therapeutics have announced that they will collaborate on the development of AL01811, a novel β-glucosidase 2 (GBA2) inhibitor and first-in-class small molecule with the potential to become a disease-modifying treatment for Parkinson’s disease.
Previous research has examined whether levels of alpha-synuclein autoantibodies (α-syn AAb) differ between patients with Parkinson’s disease and healthy controls to determine its utility as a biomarker, however, results have been inconclusive.
A primary challenge in the diagnosis of neurological disorders is differentiating between conditions that share clinical features. Absent of a clear diagnosis, proper
and effective patient care is hindered. Therefore, there is a great need for accessible diagnostic tools that help provide clarity to diagnosing clinicians.
Researchers from La Jolla Institute for Immunology have discovered a genetic signature on the circulating T cells of patients with Parkinson’s disease, which they hope can provide new avenues of research for potential treatments.
Vaxxinity, a “purpose-driven biotechnology company committed to democratizing healthcare across the globe,” announced that it has dosed its first patient with Parkinson’s disease in a Phase 1 study of the vaccine UB-312.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded two grants to AC Immune, a Swiss-based biopharmaceutical company, to support the development of molecules designed to stop the accumulation of alpha-synuclein and inhibit an inflammatory pathway in Parkinson’s disease.